These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 33443584)

  • 1. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wang L; Paller CJ; Hong H; De Felice A; Alexander GC; Brawley O
    JAMA Oncol; 2021 Mar; 7(3):412-420. PubMed ID: 33443584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
    Riaz IB; Naqvi SAA; He H; Asghar N; Siddiqi R; Liu H; Singh P; Childs DS; Ravi P; Hussain SA; Murad MH; Boorjian SA; Sweeney C; Van Allen EM; Bryce AH
    JAMA Oncol; 2023 May; 9(5):635-645. PubMed ID: 36862387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
    Wang L; Hong H; Alexander GC; Brawley OW; Paller CJ; Ballreich J
    Value Health; 2022 May; 25(5):796-802. PubMed ID: 35500949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
    Menges D; Yebyo HG; Sivec-Muniz S; Haile SR; Barbier MC; Tomonaga Y; Schwenkglenks M; Puhan MA
    Eur Urol Oncol; 2022 Dec; 5(6):605-616. PubMed ID: 35599144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
    Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis.
    Chen J; Zhang Y; Zhang X; Zhao J; Ni Y; Zhu S; He B; Dai J; Wang Z; Wang Z; Liang J; Zhu X; Shen P; Zeng H; Sun G
    Front Pharmacol; 2021; 12():789319. PubMed ID: 35115934
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    Wang L; Paller C; Hong H; Rosman L; De Felice A; Brawley O; Alexander GC
    J Natl Cancer Inst; 2022 Feb; 114(2):191-202. PubMed ID: 33830214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
    Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH
    Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
    Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
    J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
    Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
    Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Wang T; Wang X; Ding G; Liu H; Ma X; Ma J; Cui Y; Wu J
    Br J Cancer; 2024 Nov; 131(8):1363-1377. PubMed ID: 39223303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in metastatic castration sensitive prostate cancer: A Systematic review and network meta-analysis.
    Kumar J; Alam MU; Jazayeri SB; Tanneru K; Bazargani S; Shastri C; Gautam S; Koochekpour S; Shukla S; Bandyk M; Costa J; Balaji KC
    Indian J Urol; 2022; 38(3):220-226. PubMed ID: 35983120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.